EYLEA is a recombinant fusion protein consisting of portions of human Vascular Endothelial Growth Factor (VEGF) receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
EYLEA acts as a soluble decoy receptor that binds VEGF-A and PlGF with a higher affinity than their natural receptors, and thereby it inhibits the binding and activation of these cognate VEGF receptors.
EYLEA is indicated for the treatment of:
- Neovascular (wet) age-related macular degeneration (wet AMD)
- Macular oedema following central retinal vein occlusion (CRVO)
- Macular oedema secondary to branch retinal vein occlusion (BRVO)
- Diabetic macular oedema (DME)
- Myopic choroidal neovascularization (myopic CNV)